Abstract: Provided are humanized monoclonal antibodies (mAbs) or fragments thereof that bind with specificity to the Thomsen-Friedenreich (TF) human tumor antigen. Three distinct variable heavy and three variable light chains are provided, and can be combined to make a total of twenty-five distinct heavy and light chain combinations. Methods of using the mAbs and fragments thereof for cancer therapy and diagnostic imaging are provided, as are methods for making the mAbs and fragments thereof. In vitro cell cultures that express the mAbs and fragments thereof, and kits are also provided.

Abstract: Provided are humanized monoclonal antibodies (mAbs) or fragments thereof that bind with specificity to the Thomsen-Friedenreich (TF) human tumor antigen. Three distinct variable heavy and three variable light chains are provided, and can be combined to make a total of twenty-five distinct heavy and light chain combinations. Methods of using the mAbs and fragments thereof for cancer therapy and diagnostic imaging are provided, as are methods for making the mAbs and fragments thereof. In vitro cell cultures that express the mAbs and fragments thereof, and kits are also provided.

Abstract: Provided are humanized monoclonal antibodies (mAbs) or fragments thereof that bind with specificity to the Thomsen-Friedenreich (TF) human tumor antigen. Three distinct variable heavy and three variable light chains are provided, and can be combined to make a total of twenty-five distinct heavy and light chain combinations. Methods of using the mAbs and fragments thereof for cancer therapy and diagnostic imaging are provided, as are methods for making the mAbs and fragments thereof. In vitro cell cultures that express the mAbs and fragments thereof, and kits are also provided.

Abstract: Provided are humanized monoclonal antibodies (mAbs) or fragments thereof that bind with specificity to the Thomsen-Friedenreich (TF) human tumor antigen. Three distinct variable heavy and three variable light chains are provided, and can be combined to make a total of twenty-five distinct heavy and light chain combinations. Methods of using the mAbs and fragments thereof for cancer therapy and diagnostic imaging are provided, as are methods for making the mAbs and fragments thereof. In vitro cell cultures that express the mAbs and fragments thereof, and kits are also provided.

Abstract: The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF—Ag, or for detection of tumors or metastatic foci which express TF—Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF—Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF—Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metastatic foci or tumors which comprise cancer cells expressing TF—Ag.

Abstract: The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF-Ag, or for detection of tumors or metastatic foci which express TF-Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF-Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF-Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metatstatic foci or tumors which comprise cancer cells expressing TF-Ag.

Abstract: Carbohydrate antigen-nanoparticle conjugates are disclosed. Methods of making carbohydrate antigen-nanoparticle conjugates are also disclosed. The carbohydrate antigen-nanoparticle conjugates can be used to inhibit metastasis of tumor cells in mammals.

Abstract: The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF-Ag, or for detection of tumors or metastatic foci which express TF-Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF-Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF-Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metatstatic foci or tumors which comprise cancer cells expressing TF-Ag.